Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; calcium chloride dihydrate; trometamol; water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 550 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; calcium chloride dihydrate; trometamol; water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: trometamol; hydrochloric acid; sodium chloride; calcium chloride dihydrate; sodium calcium edetate; water for injections; sodium hydroxide - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; sodium chloride; calcium chloride dihydrate; water for injections; trometamol; sodium hydroxide; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; trometamol; sodium chloride; hydrochloric acid; calcium chloride dihydrate; sodium hydroxide; water for injections - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; trometamol; calcium chloride dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; trometamol; calcium chloride dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid - visipaque is indicated, in adult patients, for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa).

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; trometamol; calcium chloride dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iodixanol, quantity: 652 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; trometamol; calcium chloride dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid - this medicinal product is for diagnostic use only. visipaque is indicated in adult patients for angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography, contrast-enhanced computed tomography of the head and body, excretory urography and venography. in arteriography, visipaque may be used for both conventional radiography and digital subtraction angiography (dsa). in children, visipaque is indicated for cardioangiography, urography, ct enhancement and studies of the upper gastrointestinal tract.

United States - English - NLM (National Library of Medicine)

ge healthcare inc. - iodixanol (unii: hw8w27htxx) (iodixanol - unii:hw8w27htxx) - visipaque is indicated in for: adult and pediatric patients 12 years of age and older - (270 and 320 mg iodine/ml) intra-arterial digital subtraction angiography (ia-dsa). - (320 mg iodine/ml) angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. pediatric patients less than 12 years of age - (320 mg iodine/ml) angiocardiography, cerebral arteriography, and visceral arteriography. adult and pediatric patients 12 years of age and older - (270 and 320 mg iodine/ml) ct imaging of the head and body. - (270 and 320 mg iodine/ml) excretory urography. - (270 mg iodine/ml) peripheral venography. - (320 mg iodine/ml) coronary computed tomography angiography (ccta) to assist in the diagnostic evaluation of patients with suspected coronary artery disease. pediatric patients less than 12 years of age - (270 mg iodine/ml) ct imaging of the head and body. - (270 mg iodine/ml) excretory urography. visipaque is contraindic